point of care | GenomeWeb

point of care

Theranos CEO Elizabeth Holmes speaks at the AACC 2016 meeting

At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.

Originally published Oct. 31.
NEW YORK (GenomeWeb) – Spartan Bioscience is gearing up to commercialize its CYP2C19 test in Canada in the point-of-care setting, a previously untapped market for the company.

NEW YORK (GenomeWeb) — A public-private team led by researchers at the Keck Graduate Institute of Life Sciences has been awarded just over $600,000 by the National Institutes of Health for the first year of a four-year project to further develop its point-of-care nucleic acid testing platform for

NEW YORK (GenomeWeb) — Bay Area startup Diassess has been awarded nearly $300,000 from the National Institutes of Health for the first year of a two-year project to develop a point-of-care, nucleic acid amplification-based diagnostic device for sexually transmitted infections, with an initial foc

NEW YORK (GenomeWeb) — Early-stage molecular diagnostics developer Mesa Tech International has been awarded $1 million from the National Institutes of Health to further develop its low-cost nucleic acid testing device for respiratory disease diagnosis.

Roche's acquisition of privately held Boston-area molecular diagnostics developer Iquum, announced earlier this week, is expected to fill a hole in Roche's product portfolio, gi

NEW YORK (GenomeWeb News) — Roche said today that it has acquired Iquum, a privately held company developing point-of-care molecular diagnostics.

A team from Cornell University and Cornell Weill Medical College has received a grant from the National Institute of Biomedical Imaging and Bioengineering to support early clinical development and validation of its solar-powered, point-of-care PCR to enable electricity-free diagn

Nanomal, a European Union-funded public-private consortium developing a handheld device for rapid, point-of-care molecular diagnosis of malaria and drug resistance, said this week that the instrument is a year ahead of schedule and will be ready for field testing later this year.

Nanobiosys, a four-year-old South Korean molecular diagnostics firm, has published the first description and validation study of its flagship technology, a fast, portable, and inexpensive fluidic chip-based real-time PCR instrument.


In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.